ID   KAP0_HUMAN              Reviewed;         381 AA.
AC   P10644; K7ER48; Q567S7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   10-MAY-2017, entry version 202.
DE   RecName: Full=cAMP-dependent protein kinase type I-alpha regulatory subunit;
DE   AltName: Full=Tissue-specific extinguisher 1;
DE            Short=TSE1;
DE   Contains:
DE     RecName: Full=cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed;
GN   Name=PRKAR1A; Synonyms=PKR1, PRKAR1, TSE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=3426618; DOI=10.1016/0006-291X(87)90499-2;
RA   Sandberg M., Tasken K., Oeyen O., Hansson V., Jahnsen T.;
RT   "Molecular cloning, cDNA structure and deduced amino acid sequence for
RT   a type I regulatory subunit of cAMP-dependent protein kinase from
RT   human testis.";
RL   Biochem. Biophys. Res. Commun. 149:939-945(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2310396; DOI=10.1016/0006-291X(90)91768-N;
RA   Sandberg M., Skalhegg B., Jahnsen T.;
RT   "The two mRNA forms for the type I alpha regulatory subunit of cAMP-
RT   dependent protein kinase from human testis are due to the use of
RT   different polyadenylation site signals.";
RL   Biochem. Biophys. Res. Commun. 167:323-330(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1889088; DOI=10.1016/0092-8674(91)90433-Y;
RA   Jones K.W., Shapero M.H., Chevrette M., Fournier R.E.;
RT   "Subtractive hybridization cloning of a tissue-specific extinguisher:
RT   TSE1 encodes a regulatory subunit of protein kinase A.";
RL   Cell 66:861-872(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=8977401; DOI=10.1210/endo.138.1.4864;
RA   Solberg R., Sandberg M., Natarajan V., Torjesen P.A., Hansson V.,
RA   Jahnsen T., Tasken K.;
RT   "The human gene for the regulatory subunit RI alpha of cyclic
RT   adenosine 3', 5'-monophosphate-dependent protein kinase: two distinct
RT   promoters provide differential regulation of alternately spliced
RT   messenger ribonucleic acids.";
RL   Endocrinology 138:169-181(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-13, AND ACETYLATION AT MET-1.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   INVOLVEMENT IN PPNAD1.
RX   PubMed=12213893; DOI=10.1210/jc.2002-020592;
RA   Groussin L., Jullian E., Perlemoine K., Louvel A., Leheup B.,
RA   Luton J.P., Bertagna X., Bertherat J.;
RT   "Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic
RT   primary pigmented nodular adrenocortical disease.";
RL   J. Clin. Endocrinol. Metab. 87:4324-4329(2002).
RN   [9]
RP   INTERACTION WITH RFC2.
RX   PubMed=15655353;
RA   Gupte R.S., Weng Y., Liu L., Lee M.Y.;
RT   "The second subunit of the replication factor C complex (RFC40) and
RT   the regulatory subunit (RIalpha) of protein kinase A form a protein
RT   complex promoting cell survival.";
RL   Cell Cycle 4:323-329(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH PRKX.
RX   PubMed=16491121; DOI=10.1038/sj.onc.1209436;
RA   Glesne D., Huberman E.;
RT   "Smad6 is a protein kinase X phosphorylation substrate and is required
RT   for HL-60 cell differentiation.";
RL   Oncogene 25:4086-4098(2006).
RN   [12]
RP   INTERACTION WITH AICDA.
RX   PubMed=16387847; DOI=10.1073/pnas.0509969103;
RA   Pasqualucci L., Kitaura Y., Gu H., Dalla-Favera R.;
RT   "PKA-mediated phosphorylation regulates the function of activation-
RT   induced deaminase (AID) in B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:395-400(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   INTERACTION WITH RARA, AND FUNCTION.
RX   PubMed=20215566; DOI=10.1210/en.2009-1338;
RA   Santos N.C., Kim K.H.;
RT   "Activity of retinoic acid receptor-alpha is directly regulated at its
RT   protein kinase A sites in response to follicle-stimulating hormone
RT   signaling.";
RL   Endocrinology 151:2361-2372(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   INVOLVEMENT IN ACRDYS1, AND MUTAGENESIS OF TYR-373.
RX   PubMed=21651393; DOI=10.1056/NEJMoa1012717;
RA   Linglart A., Menguy C., Couvineau A., Auzan C., Gunes Y., Cancel M.,
RA   Motte E., Pinto G., Chanson P., Bougneres P., Clauser E., Silve C.;
RT   "Recurrent PRKAR1A mutation in acrodysostosis with hormone
RT   resistance.";
RL   N. Engl. J. Med. 364:2218-2226(2011).
RN   [25]
RP   INTERACTION WITH PJA2.
RX   PubMed=21423175; DOI=10.1038/ncb2209;
RA   Lignitto L., Carlucci A., Sepe M., Stefan E., Cuomo O., Nistico R.,
RA   Scorziello A., Savoia C., Garbi C., Annunziato L., Feliciello A.;
RT   "Control of PKA stability and signalling by the RING ligase praja2.";
RL   Nat. Cell Biol. 13:412-422(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   INVOLVEMENT IN CNC1.
RX   PubMed=22785148; DOI=10.1507/endocrj.EJ12-0040;
RA   Tung S.C., Hwang D.Y., Yang J.W., Chen W.J., Lee C.T.;
RT   "An unusual presentation of Carney complex with diffuse primary
RT   pigmented nodular adrenocortical disease on one adrenal gland and a
RT   nonpigmented adrenocortical adenoma and focal primary pigmented
RT   nodular adrenocortical disease on the other.";
RL   Endocr. J. 59:823-830(2012).
RN   [28]
RP   INTERACTION WITH C2ORF88/SMAKAP, AND SUBCELLULAR LOCATION.
RX   PubMed=23115245; DOI=10.1074/jbc.M112.395970;
RA   Burgers P.P., Ma Y., Margarucci L., Mackey M., van der Heyden M.A.,
RA   Ellisman M., Scholten A., Taylor S.S., Heck A.J.;
RT   "A small novel A-kinase anchoring protein (AKAP) that localizes
RT   specifically protein kinase A-regulatory subunit I (PKA-RI) to the
RT   plasma membrane.";
RL   J. Biol. Chem. 287:43789-43797(2012).
RN   [29]
RP   INVOLVEMENT IN CNC1.
RX   PubMed=23323113; DOI=10.4132/KoreanJPathol.2012.46.6.595;
RA   Park K.U., Kim H.S., Lee S.K., Jung W.W., Park Y.K.;
RT   "Novel Mutation in PRKAR1A in Carney Complex.";
RL   Korean J. Pathol. 46:595-600(2012).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-75; SER-77 AND SER-83,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   VARIANT CNC1 CYS-74.
RX   PubMed=15371594; DOI=10.1073/pnas.0405535101;
RA   Veugelers M., Wilkes D., Burton K., McDermott D.A., Song Y.,
RA   Goldstein M.M., La Perle K., Vaughan C.J., O'Hagan A., Bennett K.R.,
RA   Meyer B.J., Legius E., Karttunen M., Norio R., Kaariainen H.,
RA   Lavyne M., Neau J.-P., Richter G., Kirali K., Farnsworth A.,
RA   Stapleton K., Morelli P., Takanashi Y., Bamforth J.-S.,
RA   Eitelberger F., Noszian I., Manfroi W., Powers J., Mochizuki Y.,
RA   Imai T., Ko G.T.C., Driscoll D.A., Goldmuntz E., Edelberg J.M.,
RA   Collins A., Eccles D., Irvine A.D., McKnight G.S., Basson C.T.;
RT   "Comparative PRKAR1A genotype-phenotype analyses in humans with Carney
RT   complex and prkar1a haploinsufficient mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14222-14227(2004).
RN   [35]
RP   VARIANTS CNC1 ASN-9; SER-146; TYR-183; ASP-213 AND TRP-289, AND
RP   CHARACTERIZATION OF VARIANTS CNC1 ASN-9; CYS-74; SER-146; TYR-183;
RP   ASP-213 AND TRP-289.
RX   PubMed=18241045; DOI=10.1002/humu.20688;
RA   Greene E.L., Horvath A.D., Nesterova M., Giatzakis C., Bossis I.,
RA   Stratakis C.A.;
RT   "In vitro functional studies of naturally occurring pathogenic PRKAR1A
RT   mutations that are not subject to nonsense mRNA decay.";
RL   Hum. Mutat. 29:633-639(2008).
RN   [36]
RP   VARIANT ACRDYS1 HIS-373.
RX   PubMed=22464250; DOI=10.1016/j.ajhg.2012.03.003;
RA   Michot C., Le Goff C., Goldenberg A., Abhyankar A., Klein C.,
RA   Kinning E., Guerrot A.M., Flahaut P., Duncombe A., Baujat G.,
RA   Lyonnet S., Thalassinos C., Nitschke P., Casanova J.L., Le Merrer M.,
RA   Munnich A., Cormier-Daire V.;
RT   "Exome sequencing identifies PDE4D mutations as another cause of
RT   acrodysostosis.";
RL   Am. J. Hum. Genet. 90:740-745(2012).
RN   [37]
RP   VARIANTS ACRDYS1 THR-327 AND PRO-335.
RX   PubMed=22464252; DOI=10.1016/j.ajhg.2012.03.004;
RA   Lee H., Graham J.M. Jr., Rimoin D.L., Lachman R.S., Krejci P.,
RA   Tompson S.W., Nelson S.F., Krakow D., Cohn D.H.;
RT   "Exome sequencing identifies PDE4D mutations in acrodysostosis.";
RL   Am. J. Hum. Genet. 90:746-751(2012).
RN   [38]
RP   VARIANTS ACRDYS1 ARG-285; GLU-289; VAL-328 AND LEU-335.
RX   PubMed=23043190; DOI=10.1210/jc.2012-2326;
RA   Linglart A., Fryssira H., Hiort O., Holterhus P.M.,
RA   Perez de Nanclares G., Argente J., Heinrichs C., Kuechler A.,
RA   Mantovani G., Leheup B., Wicart P., Chassot V., Schmidt D.,
RA   Rubio-Cabezas O., Richter-Unruh A., Berrade S., Pereda A., Boros E.,
RA   Munoz-Calvo M.T., Castori M., Gunes Y., Bertrand G., Bougneres P.,
RA   Clauser E., Silve C.;
RT   "PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct
RT   syndromes with or without GPCR-signaling hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E2328-E2338(2012).
RN   [39]
RP   VARIANT ACRDYS1 ALA-239, AND CHARACTERIZATION OF VARIANT ACRDYS1
RP   ALA-239.
RX   PubMed=22723333; DOI=10.1210/jc.2012-1369;
RA   Nagasaki K., Iida T., Sato H., Ogawa Y., Kikuchi T., Saitoh A.,
RA   Ogata T., Fukami M.;
RT   "PRKAR1A mutation affecting cAMP-mediated G protein-coupled receptor
RT   signaling in a patient with acrodysostosis and hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E1808-E1813(2012).
RN   [40]
RP   VARIANTS ACRDYS1 THR-213 AND CYS-373, AND VARIANT ASN-227.
RX   PubMed=23425300; DOI=10.1111/cge.12106;
RA   Muhn F., Klopocki E., Graul-Neumann L., Uhrig S., Colley A.,
RA   Castori M., Lankes E., Henn W., Gruber-Sedlmayr U., Seifert W.,
RA   Horn D.;
RT   "Novel mutations of the PRKAR1A gene in patients with
RT   acrodysostosis.";
RL   Clin. Genet. 84:531-538(2013).
RN   [41]
RP   VARIANT ACRDYS1 CYS-175, CHARACTERIZATION OF VARIANTS ACRDYS1 CYS-175;
RP   THR-213; ARG-285; GLU-289; VAL-328 AND LEU-335, CHARACTERIZATION OF
RP   VARIANTS CNC1 ASP-213 AND TRP-289, AND FUNCTION.
RX   PubMed=26405036; DOI=10.1074/jbc.M115.656553;
RA   Rhayem Y., Le Stunff C., Abdel Khalek W., Auzan C., Bertherat J.,
RA   Linglart A., Couvineau A., Silve C., Clauser E.;
RT   "Functional characterization of PRKAR1A mutations reveals a unique
RT   molecular mechanism causing acrodysostosis but multiple mechanisms
RT   causing carney complex.";
RL   J. Biol. Chem. 290:27816-27828(2015).
CC   -!- FUNCTION: Regulatory subunit of the cAMP-dependent protein kinases
CC       involved in cAMP signaling in cells. {ECO:0000269|PubMed:16491121,
CC       ECO:0000269|PubMed:20215566, ECO:0000269|PubMed:26405036}.
CC   -!- SUBUNIT: The inactive holoenzyme is composed of two regulatory
CC       chains and two catalytic chains. Activation by cAMP releases the
CC       two active catalytic monomers and the regulatory dimer. PRKAR1A
CC       also interacts with RFC2; the complex may be involved in cell
CC       survival. Interacts with AKAP4. Interacts with RARA; the
CC       interaction occurs in the presence of cAMP or FSH and regulates
CC       RARA transcriptional activity. Interacts with the phosphorylated
CC       form of PJA2. Interacts with CBFA2T3 (By similarity). Interacts
CC       with PRKX; regulates this cAMP-dependent protein kinase. Interacts
CC       with C2orf88/smAKAP; this interaction may target PRKAR1A to the
CC       plasma membrane. Interacts with AICDA. {ECO:0000250,
CC       ECO:0000269|PubMed:15655353, ECO:0000269|PubMed:16387847,
CC       ECO:0000269|PubMed:16491121, ECO:0000269|PubMed:20215566,
CC       ECO:0000269|PubMed:21423175, ECO:0000269|PubMed:23115245}.
CC   -!- INTERACTION:
CC       P03259-2:- (xeno); NbExp=5; IntAct=EBI-476431, EBI-7225021;
CC       O43687-2:AKAP7; NbExp=4; IntAct=EBI-476431, EBI-10185182;
CC       Q9BSF0:C2orf88; NbExp=3; IntAct=EBI-476431, EBI-744298;
CC       Q9H0R8:GABARAPL1; NbExp=2; IntAct=EBI-476431, EBI-746969;
CC       Q9H8W4:PLEKHF2; NbExp=3; IntAct=EBI-476431, EBI-742388;
CC       P17612:PRKACA; NbExp=5; IntAct=EBI-476431, EBI-476586;
CC       P51817:PRKX; NbExp=2; IntAct=EBI-476431, EBI-4302903;
CC       P35250:RFC2; NbExp=7; IntAct=EBI-476431, EBI-476409;
CC       Q01105:SET; NbExp=2; IntAct=EBI-476431, EBI-1053182;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23115245}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P10644-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P10644-2; Sequence=VSP_054833, VSP_054834;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- TISSUE SPECIFICITY: Four types of regulatory chains are found: I-
CC       alpha, I-beta, II-alpha, and II-beta. Their expression varies
CC       among tissues and is in some cases constitutive and in others
CC       inducible.
CC   -!- PTM: The pseudophosphorylation site binds to the substrate-binding
CC       region of the catalytic chain, resulting in the inhibition of its
CC       activity.
CC   -!- DISEASE: Carney complex 1 (CNC1) [MIM:160980]: CNC is a multiple
CC       neoplasia syndrome characterized by spotty skin pigmentation,
CC       cardiac and other myxomas, endocrine tumors, and psammomatous
CC       melanotic schwannomas. {ECO:0000269|PubMed:15371594,
CC       ECO:0000269|PubMed:18241045, ECO:0000269|PubMed:22785148,
CC       ECO:0000269|PubMed:23323113, ECO:0000269|PubMed:26405036}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Intracardiac myxoma (INTMYX) [MIM:255960]: Inheritance is
CC       autosomal recessive. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 1
CC       (PPNAD1) [MIM:610489]: A rare bilateral adrenal defect causing
CC       ACTH-independent Cushing syndrome. Macroscopic appearance of the
CC       adrenals is characteristic with small pigmented micronodules
CC       observed in the cortex. Clinical manifestations of Cushing
CC       syndrome include facial and truncal obesity, abdominal striae,
CC       muscular weakness, osteoporosis, arterial hypertension, diabetes.
CC       PPNAD1 is most often diagnosed in patients with Carney complex, a
CC       multiple neoplasia syndrome. However it can also be observed in
CC       patients without other manifestations.
CC       {ECO:0000269|PubMed:12213893}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Acrodysostosis 1, with or without hormone resistance
CC       (ACRDYS1) [MIM:101800]: A form of skeletal dysplasia characterized
CC       by short stature, severe brachydactyly, facial dysostosis, and
CC       nasal hypoplasia. Affected individuals often have advanced bone
CC       age and obesity. Laboratory studies show resistance to multiple
CC       hormones, including parathyroid, thyrotropin, calcitonin, growth
CC       hormone-releasing hormone, and gonadotropin. However, not all
CC       patients show endocrine abnormalities.
CC       {ECO:0000269|PubMed:21651393, ECO:0000269|PubMed:22464250,
CC       ECO:0000269|PubMed:22464252, ECO:0000269|PubMed:22723333,
CC       ECO:0000269|PubMed:23043190, ECO:0000269|PubMed:23425300,
CC       ECO:0000269|PubMed:26405036}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cAMP-dependent kinase regulatory chain
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKAR1AID387.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M18468; AAB50922.1; -; mRNA.
DR   EMBL; M33336; AAB50921.1; -; mRNA.
DR   EMBL; S54705; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54707; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54709; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54711; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Y07642; CAA68925.1; -; mRNA.
DR   EMBL; AC079210; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC036285; AAH36285.1; -; mRNA.
DR   EMBL; BC093042; AAH93042.1; -; mRNA.
DR   CCDS; CCDS11678.1; -. [P10644-1]
DR   CCDS; CCDS62307.1; -. [P10644-2]
DR   PIR; A34627; OKHU1R.
DR   RefSeq; NP_001263218.1; NM_001276289.1. [P10644-1]
DR   RefSeq; NP_001263219.1; NM_001276290.1. [P10644-2]
DR   RefSeq; NP_001265362.1; NM_001278433.1. [P10644-1]
DR   RefSeq; NP_002725.1; NM_002734.4. [P10644-1]
DR   RefSeq; NP_997636.1; NM_212471.2. [P10644-1]
DR   RefSeq; NP_997637.1; NM_212472.2. [P10644-1]
DR   RefSeq; XP_011523285.1; XM_011524983.2. [P10644-1]
DR   RefSeq; XP_011523286.1; XM_011524984.2. [P10644-1]
DR   RefSeq; XP_011523287.1; XM_011524985.2. [P10644-1]
DR   UniGene; Hs.280342; -.
DR   UniGene; Hs.745160; -.
DR   ProteinModelPortal; P10644; -.
DR   BioGrid; 111559; 87.
DR   DIP; DIP-34368N; -.
DR   IntAct; P10644; 80.
DR   MINT; MINT-1194164; -.
DR   STRING; 9606.ENSP00000351410; -.
DR   DrugBank; DB02527; Cyclic Adenosine Monophosphate.
DR   DrugBank; DB02315; Cyclic Guanosine Monophosphate.
DR   DrugBank; DB05798; GEM-231.
DR   GuidetoPHARMACOLOGY; 1472; -.
DR   iPTMnet; P10644; -.
DR   PhosphoSitePlus; P10644; -.
DR   SwissPalm; P10644; -.
DR   DMDM; 125193; -.
DR   OGP; P10644; -.
DR   REPRODUCTION-2DPAGE; IPI00021831; -.
DR   EPD; P10644; -.
DR   MaxQB; P10644; -.
DR   PaxDb; P10644; -.
DR   PeptideAtlas; P10644; -.
DR   PRIDE; P10644; -.
DR   DNASU; 5573; -.
DR   Ensembl; ENST00000358598; ENSP00000351410; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000392711; ENSP00000376475; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000536854; ENSP00000445625; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000586397; ENSP00000466459; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000588188; ENSP00000468106; ENSG00000108946. [P10644-2]
DR   Ensembl; ENST00000589228; ENSP00000464977; ENSG00000108946. [P10644-1]
DR   GeneID; 5573; -.
DR   KEGG; hsa:5573; -.
DR   UCSC; uc002jhg.5; human. [P10644-1]
DR   CTD; 5573; -.
DR   DisGeNET; 5573; -.
DR   GeneCards; PRKAR1A; -.
DR   GeneReviews; PRKAR1A; -.
DR   HGNC; HGNC:9388; PRKAR1A.
DR   HPA; CAB019378; -.
DR   HPA; HPA049979; -.
DR   MalaCards; PRKAR1A; -.
DR   MIM; 101800; phenotype.
DR   MIM; 160980; phenotype.
DR   MIM; 188830; gene.
DR   MIM; 255960; phenotype.
DR   MIM; 610489; phenotype.
DR   neXtProt; NX_P10644; -.
DR   OpenTargets; ENSG00000108946; -.
DR   Orphanet; 950; Acrodysostosis.
DR   Orphanet; 280651; Acrodysostosis with multiple hormone resistance.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 1359; Carney complex.
DR   Orphanet; 615; Familial atrial myxoma.
DR   Orphanet; 189439; Primary pigmented nodular adrenocortical disease.
DR   PharmGKB; PA33754; -.
DR   eggNOG; KOG1113; Eukaryota.
DR   eggNOG; COG0664; LUCA.
DR   GeneTree; ENSGT00530000062947; -.
DR   HOGENOM; HOG000196669; -.
DR   HOVERGEN; HBG002025; -.
DR   InParanoid; P10644; -.
DR   KO; K04739; -.
DR   OMA; FDAMFPC; -.
DR   OrthoDB; EOG091G0F1K; -.
DR   PhylomeDB; P10644; -.
DR   TreeFam; TF314920; -.
DR   Reactome; R-HSA-163615; PKA activation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P10644; -.
DR   SIGNOR; P10644; -.
DR   ChiTaRS; PRKAR1A; human.
DR   GenomeRNAi; 5573; -.
DR   PRO; PR:P10644; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108946; -.
DR   CleanEx; HS_PRKAR1A; -.
DR   ExpressionAtlas; P10644; baseline and differential.
DR   Genevisible; P10644; HS.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; IEA:Ensembl.
DR   GO; GO:0097546; C:ciliary base; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0044853; C:plasma membrane raft; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:LIFEdb.
DR   GO; GO:0030552; F:cAMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004862; F:cAMP-dependent protein kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IDA:BHF-UCL.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0034199; P:activation of protein kinase A activity; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0007143; P:female meiotic division; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; IMP:UniProtKB.
DR   GO; GO:2000480; P:negative regulation of cAMP-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR012198; cAMP_dep_PK_reg_su.
DR   InterPro; IPR003117; cAMP_dep_PK_reg_su_I/II_a/b.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF02197; RIIa; 1.
DR   PIRSF; PIRSF000548; PK_regulatory; 1.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00394; RIIa; 1.
DR   SUPFAM; SSF47391; SSF47391; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   PROSITE; PS00888; CNMP_BINDING_1; 2.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; cAMP; cAMP-binding; Cell membrane;
KW   Complete proteome; Cushing syndrome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Repeat.
FT   CHAIN         1    381       cAMP-dependent protein kinase type I-
FT                                alpha regulatory subunit.
FT                                /FTId=PRO_0000205377.
FT   INIT_MET      1      1       Removed; alternate.
FT                                {ECO:0000250|UniProtKB:P00514}.
FT   CHAIN         2    381       cAMP-dependent protein kinase type I-
FT                                alpha regulatory subunit, N-terminally
FT                                processed.
FT                                /FTId=PRO_0000434354.
FT   NP_BIND     137    254       cAMP 1.
FT   NP_BIND     255    381       cAMP 2.
FT   REGION        1    136       Dimerization and phosphorylation.
FT   MOTIF        96    100       Pseudophosphorylation motif.
FT   BINDING     202    202       cAMP 1.
FT   BINDING     211    211       cAMP 1.
FT   BINDING     326    326       cAMP 2.
FT   BINDING     335    335       cAMP 2.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:12665801}.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09456}.
FT   MOD_RES      75     75       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      77     77       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      83     83       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18318008,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19367720,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     101    101       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9DBC7}.
FT   MOD_RES     258    258       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09456}.
FT   DISULFID     18     18       Interchain (with C-39). {ECO:0000250}.
FT   DISULFID     39     39       Interchain (with C-18). {ECO:0000250}.
FT   VAR_SEQ     326    337       EIALLMNRPRAA -> HLIISRRSIPLG (in isoform
FT                                2). {ECO:0000305}.
FT                                /FTId=VSP_054833.
FT   VAR_SEQ     338    381       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_054834.
FT   VARIANT       9      9       S -> N (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit). {ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046894.
FT   VARIANT      74     74       R -> C (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit; dbSNP:rs137853303).
FT                                {ECO:0000269|PubMed:15371594,
FT                                ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046895.
FT   VARIANT     146    146       R -> S (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit). {ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046896.
FT   VARIANT     175    175       Y -> C (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding).
FT                                {ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_075533.
FT   VARIANT     183    183       D -> Y (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit). {ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046897.
FT   VARIANT     213    213       A -> D (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit; reduces protein degradation;
FT                                dbSNP:rs281864786).
FT                                {ECO:0000269|PubMed:18241045,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_046898.
FT   VARIANT     213    213       A -> T (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding; reduces protein
FT                                degradation).
FT                                {ECO:0000269|PubMed:23425300,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069456.
FT   VARIANT     227    227       D -> N. {ECO:0000269|PubMed:23425300}.
FT                                /FTId=VAR_069457.
FT   VARIANT     239    239       T -> A (in ACRDYS1; impairs response of
FT                                PKA to c-AMP).
FT                                {ECO:0000269|PubMed:22723333}.
FT                                /FTId=VAR_069458.
FT   VARIANT     285    285       Q -> R (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding).
FT                                {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069459.
FT   VARIANT     289    289       G -> E (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding; reduces protein
FT                                degradation).
FT                                {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069460.
FT   VARIANT     289    289       G -> W (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit; accelerates protein
FT                                degradation).
FT                                {ECO:0000269|PubMed:18241045,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_046899.
FT   VARIANT     327    327       I -> T (in ACRDYS1; dbSNP:rs387906695).
FT                                {ECO:0000269|PubMed:22464252}.
FT                                /FTId=VAR_069461.
FT   VARIANT     328    328       A -> V (in ACRDYS1; disrupts cAMP
FT                                binding). {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069462.
FT   VARIANT     335    335       R -> L (in ACRDYS1; disrupts cAMP
FT                                binding). {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069464.
FT   VARIANT     335    335       R -> P (in ACRDYS1; dbSNP:rs387906694).
FT                                {ECO:0000269|PubMed:22464252}.
FT                                /FTId=VAR_069463.
FT   VARIANT     373    373       Y -> C (in ACRDYS1).
FT                                {ECO:0000269|PubMed:23425300}.
FT                                /FTId=VAR_069465.
FT   VARIANT     373    373       Y -> H (in ACRDYS1; dbSNP:rs387906693).
FT                                {ECO:0000269|PubMed:22464250}.
FT                                /FTId=VAR_068241.
FT   MUTAGEN     373    373       Y->A: Impairs response of PKA to c-AMP.
FT                                {ECO:0000269|PubMed:21651393}.
SQ   SEQUENCE   381 AA;  42982 MW;  2D04F08CE8857A6D CRC64;
     MESGSTAASE EARSLRECEL YVQKHNIQAL LKDSIVQLCT ARPERPMAFL REYFERLEKE
     EAKQIQNLQK AGTRTDSRED EISPPPPNPV VKGRRRRGAI SAEVYTEEDA ASYVRKVIPK
     DYKTMAALAK AIEKNVLFSH LDDNERSDIF DAMFSVSFIA GETVIQQGDE GDNFYVIDQG
     ETDVYVNNEW ATSVGEGGSF GELALIYGTP RAATVKAKTN VKLWGIDRDS YRRILMGSTL
     RKRKMYEEFL SKVSILESLD KWERLTVADA LEPVQFEDGQ KIVVQGEPGD EFFIILEGSA
     AVLQRRSENE EFVEVGRLGP SDYFGEIALL MNRPRAATVV ARGPLKCVKL DRPRFERVLG
     PCSDILKRNI QQYNSFVSLS V
//
